Marc-Olivier is a Senior Associate at Forbion and joined the investment team in January 2021, investing and building companies across therapeutic areas and modalities. He was part of the team that helped build Tessellate Bio and holds an observer role on the board of portfolio company Pheon Therapeutics.

Prior to Forbion, Marc completed his PhD in Oncology at The Institute of Cancer Research in London, where he investigated the interactions between metabolic changes and DNA repair mechanisms in breast cancer. Whilst at the Institute of Cancer Research, Marc was simultaneously involved in the organization of the PanaceaStars program, an early-stage Life Sciences entrepreneurship program to support scientific founders with resources to enable the translation of their early ideas into potential companies.

Marc-Olivier also completed his MSc at McGill University, studying neuroendocrine thyroid hormone regulation. He holds a BSc in Molecular Biology with distinction from McGill. As part of his MSc and PhD, he published research in multiple leading journals including Nature, Nature Communications, and Endocrinology.